Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
06/30/2026
03/31/2026
12/31/2025
09/30/2025
06/30/2025
Revenue
251
69
61
59
60
56
Revenue Growth (YoY)
24%
23%
27%
20%
25%
19%
Cost of Revenue
63
19
15
15
14
14
Gross Profit
187
50
46
44
45
42
Selling, General & Admin
164
44
41
41
36
33
Research & Development
36
8
7
12
7
6
Operating Expenses
200
52
49
54
44
40
Other Non Operating Income (Expenses)
0
0
0
0
0
0
Pretax Income
-33
-1
-19
-13
0
0
Income Tax Expense
0
0
0
0
0
0
Net Income
-33
-1
-19
-13
0
0
Net Income Growth
725%
--
533%
--
-100%
-100%
Shares Outstanding (Diluted)
53.33
53.33
51.59
46.48
49.08
47.98
Shares Change (YoY)
11%
11%
14%
1%
12%
10%
EPS (Diluted)
-0.62
-0.02
-0.37
-0.28
0.01
0.01
EPS Growth
488%
-335%
348%
-3,018%
-134%
-128%
Free Cash Flow
6
5
-1
1
1
6
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
74.5%
72.46%
75.4%
74.57%
75%
75%
Operating Margin
-4.78%
-2.89%
-3.27%
-15.25%
1.66%
1.78%
Profit Margin
-13.14%
-1.44%
-31.14%
-22.03%
0%
0%
Free Cash Flow Margin
2.39%
7.24%
-1.63%
1.69%
1.66%
10.71%
EBITDA
-6
-1
-1
-8
2
2
EBITDA Margin
-2.39%
-1.44%
-1.63%
-13.55%
3.33%
3.57%
D&A For EBITDA
6
1
1
1
1
1
EBIT
-12
-2
-2
-9
1
1
EBIT Margin
-4.78%
-2.89%
-3.27%
-15.25%
1.66%
1.78%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are AxoGen Inc's key financial statements?
According to the latest financial statement (Form-10K), AxoGen Inc has a total asset of $0, Net loss of $0
What are the key financial ratios for AXGN?
AxoGen Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is AxoGen Inc's revenue broken down by segment or geography?
AxoGen Inc largest revenue segment is Peripheral Nerve Regeneration and Repair, at a revenue of 187,338,000 in the most earnings release.For geography, United States is the primary market for AxoGen Inc, at a revenue of 187,338,000.
Is AxoGen Inc profitable?
no, according to the latest financial statements, AxoGen Inc has a net loss of $0